肛門異形成の治療に関するエビデンス
Luiz Felipe de Campos-Lobato1, Arielle E Kanters2, Paulo Gonçalves de Oliveira1
1Department of Surgery, University of Brasília School of Medicine, Brasília, Brazil.
Clinics in colon and rectal surgery
|February 6, 2026
まとめ
高悪性度扁平上皮内病変の積極的治療は、肛門がん進行を著しく抑制する。これは、特にヒトパピローマウイルス(HPV)に感染したハイリスク者にとって、肛門異形成の積極的管理の重要性を強調するものである。
科学分野:
- 腫瘍学;ウイルス学;公衆衛生
背景:
- 高リスクヒトパピローマウイルス(HPV)によって引き起こされることが多い肛門異形成は、肛門がん(AC)の前駆病変である。;HIV陽性者を含むハイリスク集団は、ACのリスクが高い。;肛門内腫瘍(AIN)の現在の管理戦略を評価する必要がある。
研究 の 目的:
- 肛門内腫瘍(AIN)の治療に関するエビデンスをレビューすること。;ANCHOR試験に照らして、AIN治療の進歩に焦点を当てること。;肛門がん進行を抑制するために、受動的監視よりも積極的な治療を強調すること。
主な方法:
- AIN治療法の文献レビュー。;Anal Cancer/HSIL Outcomes Research Study(ANCHOR)試験のデータ分析。;様々な治療選択肢の有効性と限界の評価。
主要な成果:
- 高悪性度扁平上皮内病変(HSIL)の積極的治療は、肛門がん(AC)への進行を著しく抑制した。;受動的監視よりも積極的な治療戦略の方が効果的である。;外用薬、電気焼灼、HPVワクチンなどの様々な治療法が可能性を示しているが、限界もある。
結論:
- 特にハイリスク群において、AC発生率を低下させるためには、スクリーニングと標的介入を統合することが不可欠である。;多様な人口集団にわたる結果を検証するためには、さらなる研究が必要である。;効果的なAINスクリーニングと治療のための公衆衛生政策と臨床ガイドラインを洗練させることが不可欠である。
関連する概念動画
The Evidence for Evolution
48.3K
Genetic variations accumulating within populations over generations give rise to biological evolution. Evolutionary changes can result in the formation of novel varieties and entire new species. These changes are responsible for the diverse forms of life inhabiting the planet. The evidence for evolution suggests that all living organisms descended from common ancestors.
48.3K
Psychosexual Stages of Personality: Anal
4.1K
Sigmund Freud's theory of psychosexual development describes the anal stage as occurring between 18 months and three years of age. During this period, children derive pleasure from controlling and releasing their bowel movements. However, they quickly learn that societal expectations impose restrictions on when and where this can happen. This stage marks a critical point where children begin to develop a sense of control and mastery over their bodily functions, as well as their broader...
4.1K
Open Angle Glaucoma: Treatment
1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment
963
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
963


